CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials

Bitget2026/09/28 11:32

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

CervoMed disclosed Phase 1 study results for a new neflamapimod 50 mg tablet, positioning it for twice-daily dosing.
The new formulation is intended to deliver steadier drug levels while reducing dosing frequency, addressing variability seen with the prior capsule.
FDA lifted a prior plasma exposure cap, removing a key constraint on dose escalation in upcoming trials.
Future clinical trials are planned to test a 100 mg twice-daily regimen, aiming for stronger expected activity with manageable tolerability.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280730PRIMZONEFULLFEED9834644) on September 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

CervoMed plans neflamapimod 100 mg twice-daily regimen for future clinical trials

You may also like

Crypto prices